Cellectar Q3 net loss $4.4M ($1.41/sh); cash $12.6M; progress on EU conditional marketing for iopofosine

Cellectar Biosciences, Inc.

2025-Q3 EPS reported -$7.82 vs consensus -$2.58 ▼ miss (-203.3%)

Net loss narrowed to $4.4M ($1.41/sh) from $14.7M ($11.18/sh) YoY; R&D spending fell to $2.5M.
Cash $12.6M at Sep 30, plus $5.8M from Oct warrant exercises; runway into Q3 2026.
EMA SAWP confirmed iopofosine I 131 may qualify for Conditional Marketing Approval in WM; submission planned 2026.
Phase 1b of CLR 125 (Auger-emitter) for triple-negative breast cancer initiated; RPDD granted for iopofosine in pediatric high-grade glioma.
Raised ~$12.7M in Q3; funds to advance TNBC study and EMA application.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.